Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...

Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...